Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 55, No 1 (2021)
Guidelines
Submitted: 2020-10-16
Accepted: 2020-12-15
Published online: 2021-01-28
View PDF Download PDF file
Get Citation

Migraine treatment recommendations developed by an Expert Group of the Polish Headache Society, the Headache Section of the Polish Neurological Society, and the Polish Pain Society

Adam Stępień1, Wojciech Kozubski2, Jacek J. Rożniecki3, Izabela Domitrz4
DOI: 10.5603/PJNNS.a2021.0007
·
Pubmed: 33507529
·
Neurol Neurochir Pol 2021;55(1):33-51.
Affiliations
  1. Department of Neurology, Military Institute of Medicine in Warsaw, Szaserów 128, 04-141 Warsaw, Poland
  2. Department of Neurology, Charles Marcinkowski University of Medical Sciences,, ,,, Przybyszewskiego 49, 60-355 Poznan, Poland
  3. Medical University of Lodz, Department of Neurology, Stroke and Neurorehabilitation, 22 Kopcinskiego Street, 90-153 Lodz, Poland
  4. Department of Neurology, Medical Faculty, Medical University of Warsaw, Warsaw, Poland.

open access

Vol 55, No 1 (2021)
Guidelines
Submitted: 2020-10-16
Accepted: 2020-12-15
Published online: 2021-01-28

Abstract

Not available

Abstract

Not available

Full Text:

View PDF Download PDF file
Get Citation

Keywords

recommendations, guidelines, migraine, headaches, PTBG/PHS

About this article
Title

Migraine treatment recommendations developed by an Expert Group of the Polish Headache Society, the Headache Section of the Polish Neurological Society, and the Polish Pain Society

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 1 (2021)

Article type

Guidelines

Pages

33-51

Published online

2021-01-28

Page views

3063

Article views/downloads

4019

DOI

10.5603/PJNNS.a2021.0007

Pubmed

33507529

Bibliographic record

Neurol Neurochir Pol 2021;55(1):33-51.

Keywords

recommendations
guidelines
migraine
headaches
PTBG/PHS

Authors

Adam Stępień
Wojciech Kozubski
Jacek J. Rożniecki
Izabela Domitrz

References (147)
  1. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009; 16(9): 968–981.
    CrossRefPubMed
  2. Orr SL, Friedman BW, Christie S, et al. Management of adults with Acute Migraine in Emergency Department: The American Society Evidence Assessment of Parental Pharmacotherapies. Headache. 2016; 56: 911–940.
  3. Domitrz I, Kozubski W. Rekomendacje diagnostyczno-terapeutyczne postępowania w migrenie. Pol. Przegląd Neurol. 2019; 15(supp.B): 1–20.
  4. Stępień A. Rożniecki, Domitrz I. Leczenie pierwotnych bólów głowy. Ból. 2011; 12(4): 7–14.
  5. Dodick DW Migraine Lancet. 2018; 391(10127): 1315–1330.
    CrossRef
  6. Goadsby PJ, Holland PR. Migraine Therapy: Current Approaches and New Horizons. Neurotherapeutics. 2018; 15(2): 271–273.
    CrossRefPubMed
  7. Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013; 40(5 Suppl 3): S1–S80.
    PubMed
  8. Lipton RB, Bigal ME, Diamond M, et al. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68(5): 343–349.
    CrossRefPubMed
  9. Społeczne znaczenie migreny z perspektywy zdrowia publicznego i systemu ochrony zdrowia. Nnational Institut of Public Health (pzh) Raport. : Warszawa.
  10. Prencipe M, Gasini AR, Ferretti C. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry. 2001; 70: 377–381.
  11. Goldstein M, Chen TC. The Epidemiology of distabling headache. W: Critchley M, Advances in neurology. New York, Raven Press. 1982; 33: 377–390.
  12. Laurell K, Artto V, Bendtsen L, et al. Premonitory symptoms in migraine: A cross-sectional study in 2714 persons. Cephalalgia. 2016; 36(10): 951–959.
    CrossRefPubMed
  13. Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007; 47(10): 1418–1426.
    CrossRefPubMed
  14. May A, Bahra A, Büchel C, et al. Hypothalamic activation in cluster headache attacks. Lancet. 1998; 352(9124): 275–278.
    CrossRefPubMed
  15. Kreczmański P, Wolak T, Lewandowska M, et al. Altered functional brain imaging in migraine patients: BOLD preliminary study in migraine with and without aura. Neurol Neurochir Pol. 2019; 53(4): 304–310.
    CrossRefPubMed
  16. Chądzyński P, Kacprzak A, Domitrz W, et al. Migraine headache facilitators in a population of Polish women and their association with migraine occurrence - preliminary results. Neurol Neurochir Pol. 2019; 53(5): 377–383.
    CrossRefPubMed
  17. World Health Organization. Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000–2015. Geneva, 2016. Available at: http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Accessed October. ; 26: 2018.
  18. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012; 19(5): 703–711.
    CrossRefPubMed
  19. Stewart WF, Lipton PR, Celentano DD, et al. Prevalence of migraine headache in United States. Relation to age, icome, race and other sociodemographic factors. JAMA. 1992; 267: 64–9.
  20. Domitrz I, Lipa A, Rożniecki J, et al. Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies. Neurologia i Neurochirurgia Polska. 2020; 54(4): 337–343.
    CrossRef
  21. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia. 1988; 8: 1–96.
  22. Headache Classification Committee of the International Headache Society, International Classification of Headache Disorders. Cephalalgia. 2004; 24(S1): 9–160.
  23. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629–808.
    CrossRefPubMed
  24. Prusiński A. Migrena w praktyce lekarza rodzinnego Świat Medycyny. 2003; 3(44): 23–28.
  25. Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia. 2006; 26(6): 712–721.
    CrossRefPubMed
  26. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995; 35(7): 387–396.
    CrossRefPubMed
  27. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
    CrossRefPubMed
  28. Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015; 55(6): 778–793.
    CrossRefPubMed
  29. Diener HC, Bussone G, de Li, et al. Placebocontrolled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947–954.
  30. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia. 1995; 15(6): 531–535.
    CrossRefPubMed
  31. Dahlo¨f C, Bjo¨rkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993; 13: 117–123.
  32. Diener HC, Bussone G, de Li, et al. Placebocontrolled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947–954.
  33. Ward N, Whitney C, Avery D, et al. The analgesic effects of caffeine in headache. Pain. 1991; 44(2): 151–155.
    CrossRefPubMed
  34. Fiebich BL, Lieb K, Kammerer N, et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Neuropharmacology. 2000; 39(11): 2205–2213.
    CrossRefPubMed
  35. Yűcel A, Őzyalein S. Talu GK, Yűcel EC, Erdine S. Intarvenous administration of caffeine sodium benzoate for postura punctate headache. Rg Anesth Pain Med. 1999; 2: 51–4.
  36. Dinner HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination fort the treatment of headache: a multicentre, randomized, double – blind, single – dose, placebo – controlled parallel group study. Cephalalgia. 2005; 25: 776–787.
  37. Goldstein J, Silberstein S, Saper J, et al. Acetaminophen, Aspirin, and Caffeine Versus Sumatriptan Succinate in the Early Treatment of Migraine: Results From the ASSET trial. Headache: The Journal of Head and Face Pain. 2005; 45(8): 973–982.
    CrossRef
  38. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache. 2002; 42(9): 862–871.
    CrossRefPubMed
  39. W. Kozubski: Metamizole and hydrocortisone for the interruption of migraine attack – preliminary study. Headache Quarterly 3. ; 1992: 309.
  40. Stępień A, Kozubski W. Ocena skuteczności leczenia napadu migreny acetylosalicylanem lizyny w połączeniu z chlorowodorkiem metoklopramidu. Pol. Merk. Lek. 2004; XVII. ; 102: 615–619.
  41. Titus F, Escamilla C, Palmeira MG, et al. A Double-Blind Comparison of Lysine Acetylsalicylate plus Metoclopramide vs Ergotamine plus Caffeine in Migraine. Clinical Drug Investigation. 2001; 21(2): 87–94.
    CrossRef
  42. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005; 64(3): 463–468.
    CrossRefPubMed
  43. Láinez MJA, Galván J, Heras J, et al. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol. 2007; 14(3): 269–275.
    CrossRefPubMed
  44. Welch KM. Stroke and migraine—the spectrum of cause and effect. Funct Neurol. 2003; 18: 121–126.
  45. Ferrari M. Migraine. The Lancet. 1998; 351(9108): 1043–1051.
    CrossRef
  46. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358(9294): 1668–1675.
    CrossRefPubMed
  47. Derry S, Moore R, McQuay H. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews. 2010.
    CrossRef
  48. Colman SS, Brod MI, Krishnamurthy A, et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001; 23(1): 127–145.
    CrossRefPubMed
  49. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache. 2002; 42(1): 28–31.
    CrossRefPubMed
  50. Klapper J, Lucas C, Røsjø Ø, et al. ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004; 24(11): 918–924.
    CrossRefPubMed
  51. Smith LA, Oldman AD, McQuay HJ, et al. Eletriptan for acute migraine. Cochrane Database Syst Rev. 2001(3): CD003224.
    CrossRefPubMed
  52. Láinez M. Clinical benefits of early triptan therapy for migraine. Cephalalgia. 2004; 24 Suppl 2: 24–30.
    CrossRefPubMed
  53. Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004; 11(10): 671–677.
    CrossRefPubMed
  54. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008; 28(4): 383–391.
    CrossRefPubMed
  55. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57: 1694–1698.
  56. Ferrari M. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia. 1999; 19 Suppl 23: 2–4; discussion 4.
    CrossRefPubMed
  57. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994; 14(5): 330–338.
    CrossRefPubMed
  58. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004; 62(4): 563–568.
    CrossRefPubMed
  59. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000; 40(7): 513–520.
    CrossRefPubMed
  60. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358: 1668–1675.
  61. Dodick DW, Martin V. Triptans and CNS side effects: pharmacokinetic and metabolic mechanism. Cephalalgia. 2004; 24: 417–24.
  62. Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA Neurol. 2018; 75(5): 566–572.
    CrossRefPubMed
  63. Tfelt–Hansen P. A reviev of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia. 2006; 26: 1265–1274.
  64. Mathew N, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a premilinary report. Headache. 2000; 40: 720–723.
  65. Leniger T, Pageler L, Stude P. Diener H-Ch, Limmorth V. Comparison of intravenous valproate with intravenous lysine – acetylsalicylic acid in acute migraine attacks. Headache. 2005; 45: 42–46.
  66. Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000; 40(9): 720–723.
    CrossRefPubMed
  67. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001; 41(10): 976–980.
    CrossRefPubMed
  68. Norton J. Use of intravenous valproate sodium in status migraine. Headache. 2000; 40(9): 755–757.
    CrossRefPubMed
  69. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002; 22(5): 345–353.
    CrossRefPubMed
  70. DA approves new treatment for patients with migraine [press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine (October 11, 201).
  71. Goadsby PJ. Primary headache disorders: Five new things. Neurol Clin Pract. 2019; 9(3): 233–240.
    CrossRefPubMed
  72. Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018; 11: 2221–2227.
    CrossRefPubMed
  73. Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018; 14(6): 338–350.
    CrossRefPubMed
  74. Kuca B, Silberstein SD, Wietecha L, et al. COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018; 91(24): e2222–e2232.
    CrossRefPubMed
  75. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019; 142(7): 1894–1904.
    CrossRefPubMed
  76. Croop, R, Goadsby, PJ, Lipton, RB, Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019; 394: 737–745.
  77. Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011; 51(5): 693–706.
    CrossRefPubMed
  78. D'Amico D, Grazzi L, Usai S, et al. Disability and quality of life in headache: where we are now and where we are heading. Neurol Sci. 2013; 34 Suppl 1: S1–S5.
    CrossRefPubMed
  79. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011; 51(7): 1058–1077.
    CrossRefPubMed
  80. Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009; 22(3): 269–276.
    CrossRefPubMed
  81. Couch JR. Amitryptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33–51.
  82. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002; 22(3): 209–221.
    CrossRefPubMed
  83. Freitag FG, Collins SD, Carlson HA, et al. Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58(11): 1652–1659.
    CrossRefPubMed
  84. Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004; 291(8): 965–973.
    CrossRefPubMed
  85. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. MIGR-003 Study Group. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004; 251(8): 943–950.
    CrossRefPubMed
  86. Siniatchkin M, Andrasik F, Kropp P, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia. 2007; 27(9): 1024–1032.
    CrossRefPubMed
  87. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004(2): CD003225.
    CrossRefPubMed
  88. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008; 117(20): 2706–15; discussion 2715.
    CrossRefPubMed
  89. Maggioni F, Ruffatti S, Dainese F, et al. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain. 2005; 6(4): 322–324.
    CrossRefPubMed
  90. Product Information: HEMANGEOL(TM) Oral Solution, Propranolol HCl Oral Solution. Pierre Fabre Pharmaceuticals, Inc. (per FDA), Parsippany, NJ. ; 2014.
  91. Cupini LM, Troisi E, Placidi F, et al. Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia. 1999; 19(1): 27–31.
    CrossRefPubMed
  92. Krusz JC, Scott V. Topiramate in the treatment of chronic migraine and other headaches. Headache. 1999; 39: 363–369.
  93. Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache. 2002; 42(8): 804–809.
    CrossRefPubMed
  94. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: a possible contribution to its preventive effect in migraine. Cephalalgia. 2004; 24: 783–784.
  95. Diener HC, Bussone G, Van Oene JC, et al. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7): 814–823.
    CrossRefPubMed
  96. Taylor FR. Weight change associated with the use of migraine-preventive medications. Clin Ther. 2008; 30(6): 1069–1080.
    CrossRefPubMed
  97. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007; 115(2): 81–83.
    CrossRefPubMed
  98. Bhoi SK, Kalita J, Misra UK. Is 6 months of migraine prophylaxis adequate? Neurol Res. 2013; 35(10): 1009–1014.
    CrossRefPubMed
  99. Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004; 291(8): 965–973.
    CrossRefPubMed
  100. Silberstein SD, Neto W, Schmitt J, et al. for the MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004; 61: 490–495.
  101. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997; 17(2): 103–108.
    CrossRefPubMed
  102. FDA Drug Safety Communication. Children born to mothers who took valproate products while pregnant may have impaired cognitive development. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm261543.htm. Accessed October. ; 26: 2018.
  103. Product Information: Depakote Oral Tablets, Divalproex Sodium Oral Tablets. AbbVie Inc. (per FDA), North Chicago, IL. ; 2015.
  104. Dodick DW, Freitag F, Banks J, et al. CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009; 31(3): 542–559.
    CrossRefPubMed
  105. Bet PM, Hugtenburg JG, Penninx BW, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013; 23(11): 1443–1451.
    CrossRefPubMed
  106. Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014; 35(20): 1306–1315.
    CrossRefPubMed
  107. Mathew NT, Bendtsen L. Prophylactic pharmacotheraphy of tension-type headache. W Olesen J, Tfelt-Hansen P. The Headache, 2 wydanie, Rozdz. 88, Philadelphia; Lippioncott, Williams & Wilkins. ; 2000: 667–673.
  108. Bryson H, Wilde M. Amitriptyline. Drugs & Aging. 1996; 8(6): 459–476.
    CrossRef
  109. Becker WJ. Evidence based migraine prophylactic drug therapy. Can J Neurol Sci. 1999; 26 Suppl 3: S27–S32.
    CrossRefPubMed
  110. Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30(7): 804–814.
    CrossRefPubMed
  111. Negro A, Curto M, Lionetto L, et al. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus. 2015; 4: 826.
    CrossRefPubMed
  112. Cernuda-Morollón E, Ramón C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia. 2015; 35(10): 864–868.
    CrossRefPubMed
  113. Rothrock JF, Andress-Rothrock D, Michael A. Can botox be stopped? Discontinuing onabotulinumtoxin a therapy following remission in infrequent episodic migraine. Headache. 2016; 56: 30.
  114. VanderPluym J, Evans RW, Starling AJ. Long-Term Use and Safety of Migraine Preventive Medications. Headache. 2016; 56(8): 1335–1343.
    CrossRefPubMed
  115. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19): 1818–1826.
    CrossRefPubMed
  116. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(4): 382–390.
    CrossRefPubMed
  117. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017; 377(22): 2113–2122.
    CrossRefPubMed
  118. Skljarevski V, Oakes TM, Zhang Qi, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018; 75(2): 187–193.
    CrossRefPubMed
  119. Goldstein ED, Badi MK, Meschia JF. Treating chronic migraine in CADASIL with calcitonin gene-related peptide receptor antagonism. Neurol Clin Pract. 2019; 9(3): 277–278.
    CrossRefPubMed
  120. AHS Position Steatment on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019; 59: 1–18.
  121. Sacco European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019; 20(1): 6.
  122. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
    CrossRefPubMed
  123. Silberstein S, Merriam G. Sex hormones and headache 1999 (menstrual migraine). Neurology. 1999; 53(4 Suppl 1): S3–13.
    PubMed
  124. Mattsson P. Hormonal factors in migraine: a population based study of women aged 40-74 years. Headache. 2003; 43: 27.
  125. Angst J, Sellaro R, Merikangas KR, et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001; 104(2): 110–116.
    CrossRefPubMed
  126. Solbach P, Sargent J, Coyne L. Menstrual migraine headache; results of a controlled, experimental, outcome study of nondrug treatments. Headache. 1984; 24: 75–78.
  127. MacGregor EA, Chia H, Vohrah RC, et al. Migraine and menstruation: a pilot study. Cephalalgia. 1990; 10(6): 305–310.
    CrossRefPubMed
  128. Couturier EGM, Bomhof MAM. Knuistingh Neven A, van Duijn NI. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003; 23: 302–308.
  129. Granella F, Sances G, Pucci E, et al. Migraine with aura and reproductive life events: a case controlled study. Cephalalgia. 2000; 20(8): 701–707.
  130. Newman L, Mannix LK, Landy S, et al. Naratriptan as Short-Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache: The Journal of Head and Face Pain. 2001; 41(3): 248–256.
    CrossRef
  131. Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004; 63(2): 261–269.
    CrossRefPubMed
  132. Newman L, Mannix LK, Landy S, et al. Naratriptan as Short-Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache: The Journal of Head and Face Pain. 2001; 41(3): 248–256.
    CrossRef
  133. Pradalier A, Vincent D, Beaulieu PH, et al. Launay J-M. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. In: Proceedings of the 10th Migraine Trust Symposium. London. ; 1994: 129–132.
  134. Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache. 2014; 54(7): 1158–1172.
    CrossRefPubMed
  135. Brainin M, Barnes M, Baron JC, et al. Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol. 2004; 11(9): 577–581.
    CrossRefPubMed
  136. Silberstein S, Young WB, Mendizabal JE, et al. Efficacy of intramuscular droperidol for migraine treatment: a dose-response study. Cephalalgia 2001b. ; 21: 271–2.
  137. Tanen DA, Miller S, French T, et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003; 41(6): 847–853.
    CrossRefPubMed
  138. Kabbouche M, Vockell AL, LeCates S, et al. Tolerability and Effectiveness of Prochlorperazine for Intractable Migraine in Children. Pediatrics. 2001; 107(4): e62–e62.
    CrossRef
  139. Maizels M. Health resource utilization of the emergency department headache “Repeater” Headache. 2002; 42: 747–753.
  140. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005; 64(3): 463–468.
    CrossRefPubMed
  141. Long L, Ernst E, Ernst E. Homeopathic prophylaxis of headaches and migraine? A systematic review. J Pain Symptom Manage. 1999; 18(5): 353–357.
    CrossRefPubMed
  142. Ulusoy EK, Bolattürk ÖF. The effect of greater occipital nerve blockade on the quality of life, disability and comorbid depression, anxiety, and sleep disturbance in patients with chronic migraine. Neurol Sci. 2020; 41(7): 1829–1835.
    CrossRefPubMed
  143. Ashkenazi A, Blumenfeld A, Napchan U, et al. Interventional Procedures Special Interest Section of the American. Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research. Headache. 2010; 50(6): 943–952.
    CrossRefPubMed
  144. Riederer F, Penning S, Schoenen J. Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly Device for Migraine Prevention: A Review of the Available Data. Pain Ther. 2015 [Epub ahead of print].
    CrossRefPubMed
  145. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018; 38(6): 1038–1048.
    CrossRefPubMed
  146. Chou DE, Gross GJ, Casadei CH, et al. External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy. Neuromodulation. 2017; 20(7): 678–683.
    CrossRefPubMed
  147. Varkey E, Cider A, Carlsson J, et al. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31(14): 1428–1438.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl